Dersalazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dersalazine
Accession Number
DB06251
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
UR-12746
Product Ingredients
IngredientUNIICASInChI Key
Dersalazine SodiumBAB844203H367249-56-7YLEYSRAGECECMB-UUHDFEAYSA-M
Categories
UNII
WS1IH75AJT
CAS number
188913-58-8
Weight
Average: 600.679
Monoisotopic: 600.248503534
Chemical Formula
C35H32N6O4
InChI Key
AYEAMZDTWLXZIJ-RKOUKRECSA-N
InChI
InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38+
IUPAC Name
2-hydroxy-5-[(E)-2-{4-[(1Z)-3-[4-({2-methyl-1H-imidazo[4,5-c]pyridin-1-yl}methyl)piperidin-1-yl]-3-oxo-1-phenylprop-1-en-1-yl]phenyl}diazen-1-yl]benzoic acid
SMILES
CC1=NC2=CN=CC=C2N1CC1CCN(CC1)C(=O)\C=C(\C1=CC=CC=C1)C1=CC=C(C=C1)\N=N\C1=CC(C(O)=O)=C(O)C=C1

Pharmacology

Indication

Investigated for use/treatment in inflammatory bowel disease.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Dersalazine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Dersalazine is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Dersalazine.Approved
AcenocoumarolDersalazine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dersalazine.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Aldosterone.Experimental, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Dersalazine.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dersalazine.Approved
Ammonium chlorideThe serum concentration of Dersalazine can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Dersalazine.Approved
AncrodDersalazine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dersalazine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Dersalazine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Anistreplase.Approved
Antithrombin III humanDersalazine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanDersalazine may increase the anticoagulant activities of Apixaban.Approved
ArdeparinDersalazine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Dersalazine.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dersalazine.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Dersalazine.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Batroxobin.Experimental
BecaplerminDersalazine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Bemiparin.Approved, Investigational
BenazeprilDersalazine may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Dersalazine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Betamethasone.Approved, Vet Approved
BivalirudinDersalazine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Brinzolamide.Approved
BudesonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Dersalazine.Experimental
BumetanideDersalazine may decrease the diuretic activities of Bumetanide.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Dersalazine.Investigational
CandoxatrilDersalazine may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Dersalazine.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Dersalazine is combined with Caplacizumab.Investigational
CaptoprilDersalazine may decrease the antihypertensive activities of Captopril.Approved
Carbaspirin calciumDersalazine may increase the anticoagulant activities of Carbaspirin calcium.Experimental, Investigational
CertoparinDersalazine may increase the anticoagulant activities of Certoparin.Approved, Investigational
CiclesonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ciclesonide.Approved, Investigational
CilazaprilDersalazine may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Dersalazine.Approved
Citric AcidDersalazine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Dersalazine.Approved
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Dersalazine.Experimental
ClorindioneDersalazine may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Cortisone acetate.Approved
Dabigatran etexilateDersalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDersalazine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDersalazine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanDersalazine may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Dersalazine.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Dersalazine is combined with Deflazacort.Approved, Investigational
DelaprilDersalazine may decrease the antihypertensive activities of Delapril.Experimental
DesirudinDersalazine may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexketoprofen.Approved, Investigational
DextranDersalazine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dersalazine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dersalazine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dersalazine may increase the anticoagulant activities of Dextran 75.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Diclofenamide.Approved
DicoumarolDersalazine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Dersalazine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Dersalazine.Approved
DiphenadioneDersalazine may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dersalazine.Approved
DitazoleThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Dersalazine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidDersalazine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDersalazine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilDersalazine may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatDersalazine may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxaparinDersalazine may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Dersalazine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Dersalazine.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Dersalazine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Dersalazine.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Dersalazine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Dersalazine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Estrone sulfate.Approved
Etacrynic acidDersalazine may decrease the diuretic activities of Etacrynic acid.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateDersalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidDersalazine may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fibrinolysin.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fludrocortisone.Approved
FluindioneDersalazine may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Flurandrenolide.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone propionate.Approved
FondaparinuxDersalazine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDersalazine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilDersalazine may decrease the antihypertensive activities of Fosinopril.Approved
FurosemideDersalazine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateDersalazine may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Dersalazine.Approved, Investigational, Nutraceutical
GuacetisalDersalazine may increase the anticoagulant activities of Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Dersalazine is combined with HE3286.Investigational
Hemoglobin crosfumarilDersalazine may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinDersalazine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dersalazine.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone.Approved, Vet Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Dersalazine.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Dersalazine.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Dersalazine.Approved, Nutraceutical
IdraparinuxDersalazine may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Dersalazine.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Dersalazine.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Dersalazine.Approved, Investigational
ImidaprilDersalazine may decrease the antihypertensive activities of Imidapril.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Dersalazine is combined with Indobufen.Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Dersalazine is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Dersalazine.Investigational
LepirudinDersalazine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDersalazine may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Dersalazine.Experimental
LisinoprilDersalazine may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Dersalazine is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Medrysone.Approved
MelagatranDersalazine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Dersalazine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dersalazine.Approved
Methyl salicylateDersalazine may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Methylprednisolone.Approved, Vet Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Dersalazine.Approved
MoexiprilDersalazine may decrease the antihypertensive activities of Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Mometasone.Approved, Vet Approved
NadroparinDersalazine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDersalazine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Dersalazine.Investigational
NCX 1022The risk or severity of adverse effects can be increased when Dersalazine is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dersalazine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dersalazine.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Dersalazine.Approved
OmapatrilatDersalazine may decrease the antihypertensive activities of Omapatrilat.Investigational
OtamixabanDersalazine may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateDersalazine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateDersalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Dersalazine.Approved, Investigational
PerindoprilDersalazine may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneDersalazine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDersalazine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Dersalazine.Experimental
PiretanideDersalazine may decrease the diuretic activities of Piretanide.Experimental
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Dersalazine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Dersalazine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Dersalazine.Approved
Protein CDersalazine may increase the anticoagulant activities of Protein C.Approved
Protein S humanDersalazine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDersalazine may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilDersalazine may decrease the antihypertensive activities of Quinapril.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Dersalazine.Investigational
RamiprilDersalazine may decrease the antihypertensive activities of Ramipril.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Dersalazine.Investigational
RescinnamineDersalazine may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dersalazine.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Reteplase.Approved
ReviparinDersalazine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Dersalazine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Rimexolone.Approved
RivaroxabanDersalazine may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Rosiglitazone.Approved, Investigational
Salicylic acidSalicylic acid may increase the anticoagulant activities of Dersalazine.Approved, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Dersalazine.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Saruplase.Experimental
SelexipagThe risk or severity of adverse effects can be increased when Dersalazine is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dersalazine.Approved, Vet Approved
SpiraprilDersalazine may decrease the antihypertensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Dersalazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Streptokinase.Approved, Investigational
SulodexideDersalazine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TemocaprilDersalazine may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Dersalazine.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Dersalazine.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Tinzaparin.Approved
TioclomarolDersalazine may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Dersalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Tixocortol.Approved, Withdrawn
TorasemideDersalazine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilDersalazine may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Dersalazine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Dersalazine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Dersalazine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Triamcinolone.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Dersalazine.Approved, Investigational
Trolamine salicylateDersalazine may increase the anticoagulant activities of Trolamine salicylate.Approved
TroxerutinDersalazine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Dersalazine.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Dersalazine.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dersalazine.Approved
WarfarinDersalazine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDersalazine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilDersalazine may decrease the antihypertensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
20158304

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentUlcerative Colitis (UC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00415 mg/mLALOGPS
logP6.2ALOGPS
logP5.14ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.23ChemAxon
pKa (Strongest Basic)5.56ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area133.27 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity184.21 m3·mol-1ChemAxon
Polarizability65.09 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:19 / Updated on January 05, 2018 16:03